^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HRS-5041
i
Other names: HRS-5041, HRS5041, HRS 5041
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
Androgen receptor degrader
Related drugs:
30d
HRS-5041-102: Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants (clinicaltrials.gov)
P1, N=24, Recruiting, Atridia Pty Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HRS-5041
2ms
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
docetaxel • abiraterone acetate • prednisone • SHR-2554 • HRS-5041 • M9466
3ms
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
P1/2, N=100, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1/2 trial • Metastases
|
docetaxel • abiraterone acetate • prednisone • SHR-2554 • HRS-5041 • M9466
3ms
Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Atridia Pty Ltd.
New P1 trial
|
HRS-5041
1year
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P1, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HRS-5041
over1year
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P1, N=100, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Metastases
|
HRS-5041
Share via
